Peter Corr

Dr Peter Corr was Professor, Department of Medicine (Cardiology) and Professor, Department of Pharmacology and Molecular Biology at Washington University in St. Louis. His research has been published in more than 160 scientific manuscripts. He spent 18 years as a researcher in molecular biology and pharmacology at Washington University in St. Louis. After 18 years, Dr Corr left Washington University to become senior vice president for Discovery Research at Monsanto/Searle. Subsequently, Dr Corr became president of Worldwide Research and Development at Warner Lambert/Parke Davis until the company was acquired by Pfizer. At Pfizer, Dr Corr was initially president of Worldwide Development, and subsequently senior vice president, Science and Technology. He also headed Pfizer's worldwide pharmaceutical research and development. Dr Corr retired from Pfizer Inc in December 2006 and subsequently co-founded and is the managing general partner of Auven Therapeutics, a private equity firm pursuing a life science investment strategy where products are acquired, developed and then sold to multinational pharmaceutical firms. Dr Corr is the recipient of numerous awards including membership in the Alpha Omega Alpha National Medical Honorary Society, Award from the American Heart Association, and a Research Career Development Award from the National Institutes of Health. He received the Washington University School of Medicine Teacher of the Year Award on several occasions and, in 1990, the Washington University Distinguished Faculty Award. In 2004, Dr Corr was named a William Pitt Fellow at Pembroke College, Cambridge University, Cambridge, UK. Dr Corr was chair of the Science & Regulatory Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA); chair of PhRMA Foundation; and chair of the Hever Group, representing Chief Scientific Officers (CSO's) across the European and US based pharmaceutical industry. He is a past governor of the New York Academy of Sciences (and past chair of the board of governors) and a board member of Regents of Georgetown University. He is chair of ADC Therapeutics, SA in Lausanne, Switzerland and a board member of Imvax Inc based in Philadelphia.